Akinion Pharmaceuticals announces the publication of preclinical results of AKN-028
STOCKHOLM, SWEDEN - August 6, 2012. Akinion Pharmaceuticals AB, a Karolinska Development AB portfolio company, today announced that the article ”The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia” by Eriksson A. et al., has been published online in Blood Cancer Journal at www.nature.com/bcj .AKN-028 is a targeted, orally available, small molecule FLT3 and cKIT kinase inhibitor currently in a Phase I/II clinical trial. The published